4.7 Review

Recommendations for Treatment of Hospital-Acquired and Ventilator-Associated Pneumonia: Review of Recent International Guidelines

Journal

CLINICAL INFECTIOUS DISEASES
Volume 51, Issue -, Pages S42-S47

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1086/653048

Keywords

-

Funding

  1. Cerexa/Forest
  2. Ortho-McNeil
  3. Pfizer
  4. Boehringer Ingelheim
  5. Tibotec
  6. Wyeth
  7. Glaxo SmithLkine
  8. Protez/Novartis
  9. Merck
  10. Nabriva
  11. US Food and Drug Administration
  12. Infectious Diseases Society of America
  13. American College of Chest Physicians
  14. American Thoracic Society
  15. Society of Critical Care Medicine
  16. Pharmaceutical Research and Manufacturers of America
  17. AstraZeneca Pharmaceuticals
  18. Forest Pharmaceuticals

Ask authors/readers for more resources

Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future clinical trials. Despite some differences (mostly related to likely pathogens), there is a general agreement about the recommended approach to management. All of the reviewed guidelines invariably recommend early, appropriate antimicrobial therapy and avoidance of excessive antimicrobials by deescalation of therapy on the basis of microbiological culture results and the clinical response of the patient. Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available